{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-024556","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2026-06-09T11:16:42+00:00","discovered_at":"2026-06-09T11:20:00.213258+00:00","generated_at":"2026-06-09T11:22:08.955508+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cartesian licenses WestGene's in vivo CAR-T LNP platform for autoimmune diseases; MG trial starts 2H2026","bullets":["WestGene receives upfront payment and milestone-based payments; Cartesian gains exclusive rights to WestGene's tLNP platform for in vivo CAR-T.","Phase 1 dose-escalation study of Descartes-08 mRNA delivered via WestGene's tLNPs in generalized myasthenia gravis expected to begin 2H 2026.","In-human proof-of-concept data expected in 1H 2027; Cartesian plans to advance additional anti-BCMA CAR constructs and a BCMA TCE.","WestGene's prior clinical data showed no DLTs, SAEs, ICANS, or IRRs in up to 14 doses per patient; only Grade 1 CRS observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-024556","json":"https://secwatch.observer/filing/0001140361-26-024556.json","markdown":"https://secwatch.observer/filing/0001140361-26-024556.md","text":"https://secwatch.observer/filing/0001140361-26-024556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/0001140361-26-024556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000114036126024556/ef20075770_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:22:08.955508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}